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Edited by Lukas HuberAbstract Big MAP kinase 1 (BMK1/ERK5) plays a critical
role in pre-natal development of the cardiovascular system and
post-natal eccentric hypertrophy of the heart. Of the two
isoforms upstream of MAPK-kinase 5 (MEK5) known to exist,
only the longer MEK5a isoform potently activates BMK1. We
generated cardiac-speciﬁc constitutively active form of the
MEK5a (CA-MEK5a transgenic (Tg) mice), and observed a 3
to 4-fold increase in endogenous BMK1 activation and hyper-
phosphorylation of connexin 43 in the ventricles of the Tg
compared to wild-type mice. The CA-MEK5a-Tg-mice demon-
strated a profoundly accelerated recovery of left ventricular
developed pressure after ischemia/reperfusion. We propose a
novel role for BMK1 in protecting the heart from ischemia/
reperfusion-induced cardiac injury.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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MAPkinases are serine and threonine protein kinases that are
activated in response to a wide variety of extracellular stimuli.
Big MAP kinase 1 (BMK1/ERK5) is part of a distinct MAP-
kinase signaling pathway that is required for epithelial growth
factor-induced cell proliferation and progression through the
cell cycle [1]. In addition to growth factors, redox, hyperosmotic
stress, and pathways involving certain G-protein coupled re-
ceptors activate BMK1. The importance of BMK1 in cardio-
vascular development was supported by the observation that
BMK1 knock-out mice have impaired cardiac and vascular
development [2]. Transgenic (Tg) mice expressing a cardiac-
speciﬁc constitutively active form of MAPK-kinase 5 (MEK5),
the upstream MAPK-kinase responsible for the activation of* Corresponding authors. Fax: +1-212-305-0777.
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doi:10.1016/j.febslet.2004.03.120BMK1, demonstrated eccentric cardiac hypertrophy indicating
the role of BMK1 in post-natal cardiac development as well [3].
MEK5 was originally cloned as splice variants MEK5a
and MEK5b; both variants have distinct tissue-wide distri-
bution and cellular localization [4]. The two proteins diﬀer
by N-terminal 89 amino acids present only in the MEK5a
isoform and we recently demonstrated that MEK5a, but not
MEK5b, activates BMK1 [5]. In fact, MEK5b exhibited a
dominant-negative phenotype with respect to BMK1 acti-
vation. Since the prior report of MEK5 Tg mice used the
MEK5b isoform [3], we created Tg mice with the cardiac-
speciﬁc over expression of constitutively active form of
MEK5a (CA-MEK5a-Tg). The CA-MEK5a-Tg mice hearts
demonstrated activation of BMK1 and normal basal cardiac
function and morphology, but enhanced recovery of con-
tractile function and decreased post-ischemic cardiac dam-
age. This phenotype is in contrast to the previously
described cardio-speciﬁc CA-MEK5b-Tg mice.2. Materials and methods
2.1. Transgenic mice and genotyping
Mouse CA-MEK5a (S311D/T315D) cDNA was subcloned into a
pBluescript-based Tg vector between the 5.5-kb murine-aMHC pro-
moter and 250-bp SV-40 polyadenylation sequences. The puriﬁed
transgene fragment was injected into male pronuclei of fertilized mouse
oocytes (University of Rochester Transgenic Core). Genotype of
mouse pups was conﬁrmed by PCR analysis of tail clippings using
standard procedures.
2.2. Western blot analysis and kinase activity
After treatment, the cells were washed with PBS, harvested in 0.5 ml
of MOSLB lysis buﬀer (50 mM sodium pyrophosphate, 50 mM NaF,
50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 100 lM Na3VO4, 10 mM
HEPES, pH 7.4, 0.1% Triton X-100, 500 lM phenylmethanesulfonyl
ﬂuoride, and 10 lg/ml leupeptin) ﬂash-frozen on a dry ice/ethanol
bath. The heart homogenates were prepared with sonication and
subcellular fractionation performed as described previously [5,6]. For
Western blot analysis, cell lysates or immunoprecipitates were sub-
jected to SDS–PAGE and proteins were transferred to nitrocellulose
membranes (HybondTM-ECL, Amersham-Pharmacia, Piscataway, NJ)
and blotted as previously described [12,16]. BMK1 kinase activity was
measured by autophosphorylation [7].
2.3. Connexin 43 (Cx43) immunocytochemistry
For whole heart immunohistochemistry, the heart was perfused with
ice-cold PBS in situ, excised, and ﬁxed in 10% buﬀered formalination of European Biochemical Societies.
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mounted sections were immunostained with anti-Cx43 antibody as
previously described [8].
2.4. Measurement of left ventricular function by the Langendorﬀ
preparation and by trans-thoracic echocardiography
For Langendorﬀ perfused heart studies, CA-MEK5a-Tg mice and
wild type littermate mice were used for these experiments. Animals
were anesthetized with ketamine (50 mg/kg) and xylazine (2.5 mg/
kg), i.p., and heparinized (5000 U/kg), i.p., to protect the heart
against microthrombi. The chest was opened at the sternum and the
heart, after cannulation with a 23 G phalanged stainless steel can-
nula, quickly removed. The heart was retrogradely perfused through
the aorta in a non-circulating Langendorﬀ apparatus with KH buﬀer
(118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4,
2.5 mM CaCl2, 25 mM NaHCO3, 0.5 mM Na-EDTA and 11 mM
glucose) at a constant pressure of 80 mm Hg. The buﬀer was sat-
urated with 95% O2/5% CO2 (v/v, pH 7.4, 37 C) for 50 min. A
homemade water-ﬁlled balloon was inserted into the left ventricle
through the left atrium and was adjusted to a left ventricular end-
diastolic pressure of 5 mm Hg during initial equilibration. The distal
end of the catheter was connected to an ETH-200 Bridge Ampliﬁer
(CB Sciences, Inc) and PowerLab/200 (AD Instruments) data ac-
quisition system via a pressure transducer (DELTRAN II, Utah
Medical Products, Inc). Hearts were paced at 300 beats/min except
during ischemia. Pacing was reinitiated after three minutes of rep-
erfusion in all groups. After 25 min equilibration period, hearts were
subjected to 40 min of no-ﬂow normothermic global ischemia and
40 min reperfusion.
The cardiac function in intact wild-type and CA-MEK5a-Tg mice
was evaluated non-invasively by transthoracic echocardiography [9].
Mice were anesthetized with ketamine and xylazine, i.p., chest
shaved and EKG leads attached to the limbs. M-mode echocar-
diographic studies were performed with an Accuson Sequoia
Ultrasonograph (Mountainview, CA) using a dynamically focused
14-MHz annular array transducer applied to the left hemithorax
through a coupling gel.
2.5. Measurement of cardiac damage
Hearts were immediately removed from the Langendorﬀ appara-
tus, weighed, and frozen at )20 C. The frozen heart was sectioned
manually into 7 or 8 transverse slices of approximately equal
thickness (0.8 mm) and stained by incubation in 10% triphenyl
tetrazolium chloride (TTC) [10]. The risk area was the sum of total
ventricular area minus cavities that equals the total left ventricular
mass in this model of global no-ﬂow ischemia. The infarct size was
calculated as percent left ventricular mass. Creatine kinase and
lactate dehydrogenase were measured by the University of Roches-
ter, Department of Clinical Chemistry, and reported in clinical in-
dices (units/L) as meansS.D.
2.6. Caspase 3 activity
Hearts were tested for caspase 3-like activity at the following two
diﬀerent time points: (1) when excised and washed with KHB so-
lution (n ¼ 3) and (2) after being subjected to 40-min ischemia
followed by 120-min reperfusion (n ¼ 3). The hearts frozen in li-
quid nitrogen were homogenized with a polytron homogenizer and
centrifuged at 16 000 g for 20 min at 4 C. Protein extracts (100
lg/sample) were used to measure caspase 3-like activity using a
ﬂuorescence substrate (CaspACE, Promega). The free 7-amino-
4-methyl coumarin ﬂuorochrome released by caspase cleavage of
the ﬂuorogenic substrate was detected by excitation at 360 nm and
emission at 460 nm by an end-point assay [11]. Results were
normalized for all experiments by arbitrarily setting the caspase
activity of the vehicle-perfused hearts to 1.0 and reporting the data
as means S.D.
2.7. Statistical analysis
Data are reported as meanS.E. except where indicated. Statistical
analysis was performed with the StatView 4.0 package (ABACUS
Concepts, Berkeley, CA). Diﬀerences were analyzed with one-way or at
two-way ANOVA for repeated measurements as appropriate, followed
by Scheﬀe’s test. A P value of less than 0.05 was considered statistically
signiﬁcant.3. Results
3.1. BMK1 activation in cardiac-speciﬁc CA-MEK5a-Tg mice
To examine the eﬀect of activation of BMK1 at the whole
organ level, we created Tg mice with cardiac-speciﬁc expres-
sion of the constitutively active form of MEK5a (CA-MEK5a-
Tg). The level of Tg protein expression in three diﬀerent lines
of Tg mice was determined by Western blots using an anti-
MEK5 antibody. Because all three Tg lines showed a similar
phenotype, including the response to ischemia and reperfusion
in the Langendorﬀ preparation, we describe here the data from
line Tg-2 as the representative results for CA-MEK5a-Tg mice.
We found a 7 to 8-fold increase in the level of total MEK5a
expression relative to wild-type mice, where endogenous
MEK5a protein expression is barely detectable (Fig. 1A).
Endogenous MEK5b protein expression was more abundant
in both wild-type and CA-MEK5a-Tg hearts in agreement
with an earlier report [4] and the protein expression level did
not change within the 10 weeks observation period. The CA-
MEK5a-Tg lines exhibited normal feeding, activity, weight
gain, and survival up to our current observational period of 30
weeks compared to the wild-type littermates.
There was a concordant 3 to 4-fold increase in BMK1 ac-
tivity in CA-MEK5a-Tg mouse hearts documented by the in
vitro kinase assay and autophosphorylation of BMK1
(Fig. 1B). However, there was no signiﬁcant ERK1/2 activa-
tion in CA-MEK5a-Tg mouse hearts demonstrating a selective
BMK1 activation in our Tg mice (Fig. 1B). To further conﬁrm
BMK1 activation in these Tg mice, we examined the level of
Cx43 phosphorylation upon long-term activation of BMK1 by
CA-MEK5a, since Cx43 is an excellent BMK1 substrate [12].
In wild-type mouse hearts, Cx43 was distributed between the
non-phosphorylated and presumably the basally phosphory-
lated state, but Cx43 in CA-MEK5a-Tg hearts appeared to be
entirely hyperphosphorylated (Fig. 1C, upper). Further prob-
ing for non-phosphorylated Cx43 immunoreactive signal with
the monoclonal CX-1B1 antibody failed to reveal non-phos-
phorylated Cx43 in CA-MEK5a-Tg mouse hearts (Fig. 1C,
middle) consistent with Cx43 being highly phosphorylated in
vivo [12]. The total Cx43 immunoreactive signal was greater in
CA-MEK5a-Tg mouse hearts compared to wild-type litter-
mates, consistent with the well-known observation of easier
detergent extraction of the phosphorylated Cx43 species [6,13].
Being acutely aware of the technical issues involved in ex-
tracting plasma membrane-bound Cx43 [14], we sought to
more accurately determine Cx43 expression and subcellular
localization in wild-type and CA-MEK5a-Tg mouse hearts.
Left ventricular sections from wild type and CA-MEK5a-Tg
were probed with an anti-pan-Cx43 antibody that detects all
Cx43 isoforms. In wild-type hearts (Fig. 1D, upper), intense
Cx43 immunoreactivity was seen at discrete sites of intercel-
lular apposition, while in CA-MEK5a-Tg mouse hearts, a
signiﬁcant increase in the amount of Cx43 immunoreactive
signal within intracellular regions of hearts was observed
(Fig. 1D, lower). The immunohistochemical data suggest that
BMK1 activation results in intracellular redistribution of
Cx43, in vivo, consistent with our prior in vitro observation
[12]. In addition, it appeared that the total Cx43 immunore-
active signal was greater than in wild-type mice, which suggests
that BMK1 activation may lead to a modest upregulation of
Cx43 expression. These data strongly suggest that BMK1 is
highly activated in CA-MEK5a-Tg hearts.
Fig. 1. Phosphorylation and localization of Cx43 in wild-type and CA-MEK5a-Tg mouse hearts. (A) Lysates were prepared from 10-week-old wild-
type or Tg mice hearts and immunoblotted with a pan-MEK5 antibody. A greater expression of the MEK5a isoform was noted in the CA-MEK5a-
Tg, while the MEK5b expression remained unchanged. (B) BMK1 activation in the Triton X-100 soluble cell fraction and total BMK1 protein
loading was examined, Upper two panels. ERK1/2 activation and total ERK1/2 protein was examined, Lower two panels. These data are repre-
sentatives of at least three independent experiments with similar results. (C) The Triton X-100 soluble cell fraction was obtained from the left
ventricle and separated by SDS–PAGE. Immunoblotting with a pan-Cx43 antibody recognizes total Cx43 (phosphorylated and non-phosphory-
lated), Upper panel, or with the clonal Cx-1B1 anti-Cx43 antibody selective for non-phosphorylated Cx43, Middle panel, Ponceau S staining con-
ﬁrmed equal protein loading of all lanes, Bottom panel. (D) Immunoperoxidase staining of ventricular sections for Cx43 (brown precipitate,
arrowhead) in wild-type hearts (upper) and CA-MEK5a-Tg hearts (lower) using a pan-Cx43 antibody. Calibration bar, 100 lm.
S.J. Cameron et al. / FEBS Letters 566 (2004) 255–260 2573.2. Functional role for activated BMK1 in ischemia/reperfusion
injury in cardiac-speciﬁc CA-MEK5a-Tg mice
We next examined the basal phenotype and the behavior of
wild-type and CA-MEK5a-Tg hearts subjected to ischemia/
reperfusion. Cardiac structure and function in 10- and 30-
week-old mice was normal as assessed by gross morphometric,
histologic, and non-invasive echocardiographic measurements;
this phenotype was stable during our measurement period
extending to 60 weeks. A representative cross-section of both
wild-type and CA-MEK5a-Tg hearts showed no changes in
ventricular wall thickness suggestive of cardiomyopathy
(Fig. 2A) and M-mode echocardiographic images (Fig. 2B)
conﬁrmed normal basal ventricular dimensions and function in
live hearts (Fig. 2C). This highly speciﬁc analysis of left ven-
tricular function suggests that constitutive BMK1 activation
by the CA-MEK5a transgene had no eﬀect on the basal car-
diac function.
To examine for a potential functional consequence of
BMK1-activation in myocardial ischemia/reperfusion in vivo,
we assessed the contractile function of wild type and CA-
MEK5a-Tg hearts in the Langendorﬀ preparation. No diﬀer-
ence in basal heart rate or contractile function was noted be-
tween the wild type and CA-MEK5a-Tg hearts and all hearts
subjected to a 40-min period of global ischemia recovered their
spontaneous heart beats. To better assess the ventricular pump
function, hearts were paced at a uniform rate of 300 beats/min
pre- and post-global ischemia. In wild-type hearts, the recoveryof left ventricular developed pressure after ischemia and rep-
erfusion was around 30% of the baseline level (Fig. 3A), sug-
gestive of severe contractile dysfunction. In contrast, the
developed-pressure recovered to over 70% of baseline for the
CA-MEK5a-Tg hearts at all time points after ischemia and
during reperfusion. A similar trend was seen in dP=dtmax with a
signiﬁcantly higher recovery of this parameter observed in CA-
MEK5a-Tg hearts upon reperfusion (Fig. 3B). The results
strongly suggest that although CA-MEK5a-Tg hearts are
functionally normal and indistinguishable from wild type
hearts basally, they display signiﬁcantly greater contractile
recovery even after prolonged ischemia.
3.3. Cardiac-speciﬁc CA-MEK5a-Tg mice exposed to ischemia/
reperfusion are resistant to caspase 3 activation and
post-ischemic damage
Caspase 3 activation has been implicated as a mediator of
cardiomyocytes apoptosis [11]. Consistent with this report, we
found that caspase 3-like activity was increased after 120 min
of reperfusion in wild-type hearts (Fig. 3C). However, the
caspase 3-like activity remained unchanged in CA-MEK5a-Tg
mice, and was signiﬁcantly lower compared to wild-type
hearts. These observations in intact hearts suggest an inhibi-
tory eﬀect of BMK1 activation on caspase 3-like activity.
To assess total cardiac damage incurred by the post-ischemic/
reperfused heart, we measured the cardiac enzymes, creatine
kinase (CK) and lactate dehydrogenase (LDH) released from the
Fig. 2. Wild-type and CA-MEK5a-Tg mice show indistinguishable myocardial anatomy and basal function. (A) Hematoxylin/Eosin stained lon-
gitudinal sections from 10 week-old wild-type and CA-MEK5a-Tg mouse hearts. lv: left ventricle, rv: right ventricle. (B) Representative M-mode
echocardiographic images of intact beating hearts. Measurements are given in millimeters, except fractional shortening (FS) and ejection fraction
(EF), which are given in %. EDD: end-diastolic dimension, ESD: end-systolic dimension. (C) Echocardiographic values determined from three
separate measurements and averaged 7 mice from each group at both 10 and 30 weeks. IVSD, interventricular septum diastole; IVSS, interventricular
septum systole; LVPWD, left ventricular posterior wall diastole; LVPWS, left ventricular posterior wall systole; LVED, left ventricular end diastolic
dimension; LVES, left ventricular end systolic dimension; EF and FS.
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damage [15]. Perfusates collected from wild-type mouse hearts
after 40 min of global ischemia and 40-min reperfusion docu-
mented elevated CK and LDH levels consistent with severe
cardiac damage (Fig. 3D). CA-MEK5a-Tg mouse hearts sub-
jected to the same insult released little CK or LDH, suggesting
BMK1 activation-mediated enhanced ischemic tolerance. Since
hearts subjected to ischemia in the Langendorﬀ preparation
exhibited well-deﬁned regions of infarction, the hearts were
stained with TTC and the infarct size quantiﬁed by morphom-
etry (Fig. 3E andF). Following 40min of ischemia and 40min of
reperfusion, the total infarct size in the CA-MEK5a-Tg hearts
was smaller than in wild-type hearts (Fig. 3E and F) consistent
with the diﬀerence in the recovery of ventricular pump function.
These results are consistent with BMK1 activation having a
protective eﬀect after acute phase ischemia and reperfusion,with
preservation of contractile function.4. Discussion
To our knowledge, this is the ﬁrst study to show that
the MEK5a/BMK1 signal transduction pathway is cardio-protective in an intact heart. Nicol et al. [3] reported that
cardiac-speciﬁc expression of activated MEK5b in Tg mice
resulted in eccentric cardiac hypertrophy that progressed to
dilated cardiomyopathy and sudden death. Our cardiac-
speciﬁc MEK5a-Tg mice exhibited baseline cardiac function
indistinguishable from wild-type littermates. However, the
functional recovery of the Tg hearts after ischemia/reperfu-
sion insult was profoundly accelerated compared to wild-
type mice. The amount of cardiac enzyme released and the
physical measurements of the infarct size were consistent
with the cardio-protective eﬀect of MEK5a overexpression.
On examination, two diﬀerences between the two Tg models
were apparent: (1) MEK5 isoforms: we used MEK5a, but
Nicol et al. used MEK5b and (2) Mouse strain: we used
FVB, but Nicol et al. used C3HB6. MEK5b is 89 amino
acids shorter than MEK5a at the N-terminus and we
recently reported a novel functional diﬀerence in the way
full-length MEK5a and the shorter MEK5b splice variant
regulate BMK1 activity [16]. In fact only MEK5a activated
BMK1, while MEK5b exhibited a dominant-negative phe-
notype inhibiting CA-MEK5a or growth factor-induced ac-
tivation of BMK1. A clear constitutive activation of BMK1
assessed by in vitro kinase assay and a parallel increase in
Cx43 phosphorylation were documented in our CA-MEK5a-
Fig. 3. Cardiac selective expression of CA-MEK5a protects the heart from ischemia/reperfusion-induced contractile dysfunction and post-ischemic
cardiac injury. (A) Measurements of left ventricular developed pressure before, during, and after global (no-ﬂow) ischemia followed by reperfusion.
(B) Measurement of left ventricular dP=dtmax taken at the times indicated in panel (A). All experimental values calculated for CA-MEK5a-Tg mouse
hearts (n ¼ 5) and wild-type hearts (n ¼ 5) are represented as means S.E. (C) Caspase 3-like activity after ischemia/reperfusion in wild-type and
CA-MEK5a-Tg mouse ventricles. Results are in arbitrary units normalized to wild-type control and reported as meansS.D. (D) CK and LDH
cardiac enzymes measured in the superfusate from the heart after ischemia (n ¼ 3 for wild-type, n ¼ 4 for CA-MEK5a-Tg mice) and reported as
mean units/LS.D. (E) TTC was used as an index of damaged area in the myocardium after ischemia and reperfusion. Representative images of
TTC staining of coronal sections of the hearts from wild type and CA-MEK5a-Tg mice. (F) The infarct size calculated as percent of LV area and
reported as mean S.D. * denotes P < 0:05 and ** denotes P < 0:001.
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to deﬁne why the two CA-MEK5-Tg models exhibited dif-
ferent phenotypes.
It is well known that ischemic preconditioning protects the
heart, and we previously reported that ischemic precondi-
tioning increases the maximal BMK1 activity by approxi-
mately 3.0-fold [17]. Since we document in the present study
that activation of BMK1 by expression of CA-MEK5a
transgene is also cardio-protective, it raises the possibility thatBMK1 activation during ischemic preconditioning may medi-
ate the protective eﬀect. In a more chronic model of cardiac
pathophysiology, we reported that BMK1 activity is increased
in ischemia and pressure overload-induced cardiac hypertro-
phy [18,19]. This observation also raises the interesting possi-
bility that BMK1 activation may be a compensatory
mechanism elicited by the failing heart. Further studies are
necessary to clarify the role of BMK1 in preconditioning and
chronic cardiac pathophysiology.
260 S.J. Cameron et al. / FEBS Letters 566 (2004) 255–260While the relative resistance of CA-MEK5a-Tg hearts to
ischemia/reperfusion-injury is clear, the down-stream mecha-
nism responsible for this phenotype is unidentiﬁed. One
possible mechanism leading to cardio-protection is via phos-
phorylation of Cx43 by the activated BMK1 and uncoupling
of the gap junction between myocytes. Gap junction intercel-
lular communication augments cellular damage through pu-
tative calcium-dependent pathways and ischemic cardiac
damage may be prevented by gap junction uncoupling agents
[20]. A recent report suggests that Cx43 phosphorylation in the
myocardium is a protective mechanism against subsequent
ischemic episodes [21], although our study is the ﬁrst to suggest
this speciﬁc role to BMK1. If activated BMK1 promotes gap
junction uncoupling, as supported by the circumstantial evi-
dence reported herein, the protective eﬀect of activated BMK1
against hypoxia/reperfusion-injury could at least partially be
attributed to BMK1-mediated gap junction blockade. How-
ever, evidence for the role of gap junctions in the causal rela-
tionship between activated BMK1 and relative resistance to
ischemic cardiac damage is circumstantial and further studies
will be required. Nevertheless, our observation that Cx43 is
predominantly phosphorylated in the CA-MEK5a-Tg mice
with an apparent redistribution from the plasma membrane to
cytosol is consistent with this hypothesis.
Recent reports suggest other mechanisms whereby BMK1
activation may provide protection against ischemia/reperfu-
sion-injury. BMK1 activation phosphorylates Bad and inhibits
apoptosis in endothelial cells [22]. The relation between BMK1
and Bad phosphorylation may be indirect, however, in our
current study we demonstrated a phenomenological reduction
in ischemia/reperfusion-induced caspase 3 activation in CA-
MEK5a-Tg mice. Therefore, modulation of apoptosis could
contribute to the protective eﬀect exhibited byBMK1 activation
even in the acute global ischemia/reperfusion model employed.
Recently, we also found that BMK1 activation increases
PPARc activation via direct association with the hinge-helix1
region of PPARc [23]. Since PPARc ligands have been shown to
protect against ischemia/ reperfusion injury [24,25], it is also
possible that the protective eﬀect of BMK1 activation may be
due to activation of endogenous PPARc. Further investigation
is necessary to determine the exact protective mechanisms
operating down-stream of BMK1 activation.
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